Seeking Alpha

An experimental Amgen (AMGN -0.8%) drug shows it has the potential to lower bad cholesterol via...

An experimental Amgen (AMGN -0.8%) drug shows it has the potential to lower bad cholesterol via an injected monoclonal antibody designed to inhibit the action of a protein called PCSK9, which is involved with the regulation of LDL (bad cholesterol). Sanofi (SNY) and Regeneron (REGN) are believed to have progressed the most in developing products that target PCSK9.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs